皮肤中的α-synuclein作为帕金森病的高质量生物标志物
Haoran Peng1, Siyuan Chen2, Shaopu Wu2
1Department of Neurology, People's Hospital of Henan University, Zhengzhou, Henan 450003, China; Department of Neurology, Henan Provincial People's Hospital, Zhengzhou, Henan 450003, China.
Journal of the neurological sciences
|July 16, 2023
概括
皮肤α-synuclein (α-Syn) 显示为早期帕金森病 (PD) 诊断的生物标志物具有前途. 评估皮肤α-Syn为PD检测和管理提供了一种方便而敏感的方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 帕金森病 (PD) 涉及多巴胺能神经元的丧失和主要由α-synuclein (α-Syn) 组成的Lewy体 (LBs) 的形成.
- α-Syn与PD病理学有关,其在皮肤等外围组织中的存在表明了诊断潜力.
研究的目的:
- 审查α-Syn.的生化和结构特征.
- 在中枢神经系统,生物流体和外围组织中绘制α-Syn物种的分布图.
- 批判性地分析测量皮肤α-Syn用于PD诊断的研究,并探索其未来的临床应用.
主要方法:
- 文献综述综合了α-Syn.的生化,聚合和结构数据.
- 绘制α-Syn在各种生物体内分布的地图.
- 对PD皮肤α-Syn评估现有研究的比较分析.
主要成果:
- α-Syn是莱维体的关键组成部分,在中枢神经系统和外围神经系统中都能找到.
- 皮肤α-Syn评估表明具有高灵敏度,特异性和可重复性的潜力.
- 皮肤活检为PD生物标志物检测提供了一种最小侵入性和患者可接受的方法.
结论:
- 皮肤α-Syn代表了早期帕金森病诊断的一个有前途的生物标志物.
- 未来的研究应该集中在完善皮肤活检技术和验证临床实用性的发现.
- 皮肤α-Syn评估可能会显著影响PD临床试验,决策和治疗发展.
更多相关视频
12:01Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
10.8K
09:27Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains
Published on: January 5, 2016
17.4K
相关概念视频
Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
Parkinson's Disease: Overview
604
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
604
